Vaccines for Tomorrow

The scope of Sanofi Pasteur’s Research & Development activities is vast and complex, encompassing the entire chain of events before a new vaccine becomes available – from understanding a disease and its biological foundations, to clinical development and testing, to obtaining health authorities’ approval for marketing the new vaccine.

We have currently vaccines in development or submitted for approval to meet the specific needs of different segments of the population (influenza, vaccines combination, etc.) or unmet medical needs (respiratory syncytial virus, etc.).

PHASE I PHASE II PHASE III REGISTRATION
Herpes Simplex Virus Type 2
HSV-2 therapeutic vaccine
 
Tdap US
Tdap booster
 
MenQuadfiTM
Meningococcal ACYW
conjugate vaccine,
EU 1y+, US/EU 6w+
 
Fluzone® QIV HD
Quadrivalent inactivated influenza vaccine – High dose
Respiratory syncytial virus
Infants 4-month and older vaccinesGet more information
 
HIV
Viral vector prime & rgp120 boost vaccine
 
Pediatric pentavalent vaccine
DTP-Polio-Hib Japan
 
MenQuadfiTM
Adv. Gen. Meningococcal ACYW conjugate vaccine, 2y+ (U.S.)
Pneumococcal Conjugate Vaccine (PCV) 1
     
Shan 6
DTP-HepB-Polio-Hib
Pediatric hexavalent vaccine
   
       
VerorabVax® (VRVg)
   
       
nirsevimab 2
Respiratory syncytial virus
Monoclonal antibodyGet more information
   
  New molecular entities   Additional indications   Publication date: july 2019

(1) Developed in collaboration with SK
(2) Developed in collaboration with AstraZeneca

Related article

Inoculation Innovation: Bringing New Technology to Vaccines

This website uses cookies to track its audience and improve its content. By continuing to browse this website, you agree to the use of such cookies.

Click here for more information on cookies
OK